Sign in
Not yet recruitingPhase 3

Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis

Key facts

Who runs it
Beijing Ditan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
778 people, planned
Started
15 Nov 2026
Expected to end
22 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Minocycline
  • Minocycline placebo
  • Aqueous crystalline penicillin G
Record updated
29 October 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Age 18-80 years
  • Diagnosis of neurosyphilis according to the Guidelines for the Diagnosis and Treatment of Syphilis, Gonorrhea and Genital Chlamydia trachomatis Infection (2020)
  • Cognitive impairment (MMSE 10-26) or ischemic stroke-like episodes (time from onset to randomization ≤14 days, NIHSS 1-20)
  • Written informed consent provided by the patient or their legally authorized representative

Who cannot take part

  • Intravenous or intramuscular ceftriaxone for neurosyphilis within 1 month before enrolment (a single intramuscular dose of ceftriaxone for another infection is not exclusionary)
  • Use of tetracycline antibiotics within 1 month before enrolment
  • Systemic immunosuppression meeting any of the following criteria: use of systemic glucocorticoids (oral or intravenous) within 3 months before enrolment (prednisone-equivalent dose >10 mg/day for >2 weeks); current use of immunosuppressants (including but not limited to methotrexate, azathioprine, ciclosporin, mycophenolate mofetil, TNF-α inhibitors, or JAK inhibitors); or discontinuation of immunosuppressants within <4 weeks or <5 half-lives (whichever is longer)
  • Current participation in another investigational drug or device trial
  • Allergy or resistance to penicillin or tetracycline antibiotics (including minocycline)
  • History of psychiatric disorders (e.g., schizophrenia or depression)
  • Cognitive impairment from other causes (e.g., Alzheimer's disease, frontotemporal dementia, thyroid dysfunction, folate/vitamin B12 deficiency, or alcohol use disorder)
  • Ischaemic stroke clearly attributable to other aetiologies
  • Active co-infection with central nervous system opportunistic pathogens (e.g., tuberculous meningitis, cryptococcal meningitis, toxoplasmic encephalitis, or cytomegalovirus encephalitis)
  • Other central nervous system or systemic diseases causing abnormal cerebrospinal fluid parameters (including but not limited to autoimmune encephalitis, multiple sclerosis, central nervous system tumours, systemic lupus erythematosus, antiphospholipid syndrome, sarcoidosis, or systemic vasculitis)
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation or unable to comply with the protocol
  • HIV infection meeting any of the following criteria: screening CD4+ T-cell count <200 cells/μL; or virological failure, defined as receiving antiretroviral therapy for ≥6 months with two consecutive plasma HIV RNA levels >200 copies/mL (measured 2-4 weeks apart)
  • Severe renal impairment (serum creatinine >3.0 mg/dL [265.2 μmol/L], glomerular filtration rate <30 mL/min/1.73 m², or on dialysis) or severe hepatic impairment (ALT or AST >3 × upper limit of normal)
  • Pre-morbid modified Rankin Scale (mRS) score >2
  • Severe underlying comorbidities with an expected life expectancy of <1 year
  • Pregnancy or lactation; or women of childbearing potential with a negative pregnancy test who decline to use effective contraception

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Neurosyphilis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Study Objective: Neurosyphilis remains a major clinical challenge: despite standard first-line therapy with intravenous penicillin G, as recommended by international and Chinese guidelines, approximately 30% of patients have residual neurological impairment. Minocycline, a tetracycline antibiotic, has both anti-Treponema pallidum activity and independent anti-inflammatory and neuroprotective effects. We therefore designed a prospective, multicenter, randomized, double-blind, placebo-controlled trial to evaluate whether the addition of minocycline to penicillin, as compared with penicillin monotherapy, improves the 6-month rate of favorable neurological outcomes in patients with neurosyphilis. This trial will provide evidence-based evidence for the treatment of neurosyphilis. Inclusion Criteria: 1)Age 18-80 years; 2)Diagnosis of neurosyphilis according to the Guidelines for the Diagnosis and Treatment of Syphilis, Gonorrhea and Genital Chlamydia trachomatis Infection (2020); 3)Cognitive impairment (MMSE score 10-26) or ischemic stroke-like episodes (time from onset to randomization ≤14 days, NIHSS score 1-20); 4)Written informed consent provided by the patient or their legally authorized representative. Intervention: Participants will be randomly assigned ( by chance ) to one of two groups. Group 1 will receive standard intravenous penicillin therapy plus oral minocycline for 28 days. Group 2 will receive standard intravenous penicillin therapy plus oral placebo for 28 days. All participants will receive standard penicillin treatment. Participants and their doctors will not know which group they are in. Follow-up: Participants will be followed for up to 12 months, with five follow-up visits: baseline (before treatment initiation), end of intravenous penicillin treatment (Day 12 ± 2 days), end of minocycline treatment (Day 28 + 2 days), 6 months post-treatment (Month 6 ± 7 days), and 12 months post-treatment (Month 12 ± 7 days). Assessments will include standardized neurological function scales for favorable neurological outcomes, cognitive function, neurological deficits, and activities of daily living; cerebrospinal fluid and serum efficacy marker testing; and brain MRI.

Read full original descriptionShow less

Potential Benefits and Risks: Participants may or may not benefit from participating in this study. All participants will receive standard treatment for neurosyphilis. The main risks are complications that may occur during study procedures (such as lumbar puncture, or allergic reactions to penicillin) and possible side effects of minocycline, including dizziness, vestibular side effects, nausea, or skin sensitivity to sunlight. The study team will closely monitor participants for any adverse reactions. Importance of This Study: If minocycline does help improve neurological outcomes, it could become a new treatment option for patients with neurosyphilis, thereby helping to reduce the occurrence of neurological sequelae. The implementation of this study will provide evidence-based evidence for the treatment of neurosyphilis.

The 2 groups in the trial

  • Penicillin plus MinocyclineTreatment being tested

    Participants will receive standard intravenous aqueous crystalline penicillin G (18-24 million units/day for 10-14 days) plus oral minocycline (200 mg loading dose on Day 1, followed by 100 mg every 12 hours) for 28 days.

    Treatment: Minocycline and Aqueous crystalline penicillin G

  • Penicillin plus PlaceboPlacebo, for comparison

    Participants will receive standard intravenous aqueous crystalline penicillin G (18-24 million units/day for 10-14 days) plus oral matching minocycline placebo (200 mg loading dose on Day 1, followed by 100 mg every 12 hours) for 28 days.

    Treatment: Minocycline placebo and Aqueous crystalline penicillin G

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (MIN-ADD)
Criteria questions
Built from NCT07904533, who can take part
Record updated
29 October 2026